AbbVie ABBV remains a dominant force in the immunology space, powered by the continued uptake of its two blockbuster ...

(Reuters) -AbbVie on Friday raised its 2027 forecast for sales of its immunology drugs Skyrizi and Rinvoq to $27 billion, up $6 billion from its previous prediction. The Chicago-based drugmaker has ...

In an echo of the pattern laid last year, following a record-high outlay at the very beginning of the year, TV drug ad spending has crept downward as 2025 has gone on. According to data shared with ...

It was déjà vu all over again for TV drug ad spending in August, as the top 10 spenders barely deviated from July’s list and turned in a combined total nearly identical to the preceding month’s haul.

AbbVie ABBV has successfully navigated the loss of exclusivity (LOE) for its flagship drug, Humira, by launching two newer immunology medicines, Skyrizi and Rinvoq. Investors will be most keen to know ...